SCNI NASDAQ
Scinai Immunotherapeutics Ltd.
1W: -14.2%
1M: -43.2%
3M: +394.8%
YTD: +82.3%
1Y: -4.3%
3Y: -84.9%
5Y: -99.4%
$1.33
+0.02 (+1.53%)
Weekly Expected Move ±34.0%
$0
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Income Trends
Revenue
$658K
+0.0% ▲
Gross Profit
-$580K
-13.1% ▼
Operating Income
-$9M
+11.0% ▲
Net Income
$5M
+173.8% ▲
EPS (Diluted)
$6.00
+135.7% ▲
EBITDA
-$7M
+24.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $658K |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $709K | $748K | $560K | $513K | $1M |
| Gross Profit | -$709K | -$748K | -$560K | -$513K | -$580K |
| Gross Margin | — | — | — | — | -88.1% |
| R&D Expenses | $16M | $3M | $6M | $5M | $6M |
| SG&A Expenses | $5M | $8M | $5M | $5M | $3M |
| Operating Expenses | -$2M | $11M | $11M | $10M | $8M |
| Operating Income | $2M | -$11M | -$11M | -$10M | -$9M |
| Operating Margin | — | — | — | — | -1312.8% |
| Interest Expense | $349K | $3M | $5M | $8K | $1M |
| Income Before Tax | -$1M | -$8M | -$6M | -$6M | $5M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1M | -$8M | -$6M | -$6M | $5M |
| Net Margin | — | — | — | — | 728.9% |
| EPS (Diluted) | $-12.40 | $-80.00 | $-30.80 | $-16.80 | $6.00 |
| EBITDA | $3M | -$10M | -$10M | -$9M | -$7M |
| Shares Outstanding | 110815 | 141144 | 188519 | 390657 | 806368 |